IFNG and acquired immunodeficiency: Encouraging evidence is emerging for the efficacy of rituximab, an anti-CD20- monoclonal antibody that leads to depletion of B lymphocytes, in IFNγ AAb-mediated acquired immunodeficiency (19, 63, 64).